Pipeline Developments, Product Recalls, Clinical Trial Results, Recognitions, and New Appointments - Research Report on Johnson

Pipeline Developments, Product Recalls, Clinical Trial Results, Recognitions,
and New Appointments - Research Report on Johnson & Johnson, Amgen, Regeneron,
                       UnitedHealth, and Bristol-Myers

PR Newswire

NEW YORK, September 18, 2013

NEW YORK, September 18, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Investors' Reports announced new research reports highlighting Johnson
& Johnson (NYSE: JNJ), Amgen, Inc. (NASDAQ: AMGN), Regeneron Pharmaceuticals
Inc. (NASDAQ: REGN), UnitedHealth Group Inc. (NYSE: UNH), and Bristol-Myers
Squibb Co. (NYSE: BMY). Today's readers may access these reports free of
charge - including full price targets, industry analysis and analyst ratings -
via the links below.

Johnson & Johnson Research Report

On September 12, 2013, the New York Times reported that Janssen, the
pharmaceutical unit of Johnson & Johnson (Johnson & Johnson), informed doctors
and patients on September 11, 2013, that it was recalling one lot of Risperdal
Consta, an injectable antipsychotic treatment, after routine testing turned up
evidence of mold. Further, the New York Times reported that a week earlier,
Johnson & Johnson had recalled 200,000 bottles of liquid Motrin for infants
because they may contain tiny particles of plastic. Johnson & Johnson stated
that in both cases risk to patients was low and it had received no reports of
serious harm. The Full Research Report on Johnson & Johnson - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:


Amgen, Inc. Research Report

On September 11, 2013, Amgen, Inc. (Amgen) announced the publication of a
biomarker analysis of Vectibix (panitumumab) in combination with FOLFOX, a
type of oxaliplatin-based chemotherapy, for the first-line treatment of
patients with metastatic colorectal cancer (mCRC). According to the analysis
published in the New England Journal of Medicine, RAS mutations (mutations
found in exons 2, 3, and 4 of KRAS and NRAS), beyond the known KRAS exon 2
mutations, predict lack of response to Vectibix in combination with FOLFOX.
Jean-Yves Douillard, M.D., Ph.D., Professor of Medical Oncology, Centre R.
Gauducheau, France and PRIME Trial Lead Investigator and Author, stated,
"While the KRAS exon 2 biomarker is well-known and has facilitated selection
of patients more likely to respond to anti-EGFR treatment, we found that there
were still some patients who didn't benefit from treatment. This analysis is
important as it furthers our understanding of tumor genetics and allows
physicians to more accurately match patients to effective treatments." The
Full Research Report on Amgen, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.investorsreports.com/report/2013-09-16/AMGN]


Regeneron Pharmaceuticals Inc. Research Report

On September 10, 2013, Regeneron Pharmaceuticals Inc. (Regeneron) announced
that Robert E. Landry has been appointed as Senior Vice President, Finance. In
addition, the Company stated that Mr. Landry will take on the position of CFO
of Regeneron on October 1, 2013. According to the Company, Mr. Landry will be
responsible for all financial functions, including Controller's, Treasury,
Financial Planning, Tax, and Internal Audit. Regeneron added that its current
Chief Financial Officer, Murray A. Goldberg, will transition to a new role as
Senior Vice President, Administration, in preparation for his retirement at
the end of 2014. The Company further reported that Goldberg will continue to
be responsible for Alliance Management and various administrative functions.
The Full Research Report on Regeneron Pharmaceuticals Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:


UnitedHealth Group Inc. Research Report

On September 13, 2013, UnitedHealth Group Inc. (UnitedHealth) announced that
it has been included in the Dow Jones Sustainability North America Index (DJSI
NA) and the Dow Jones Sustainability World Index (DJSI W). The Company said
that it ranked first among its peers in health care providers and services
industry sector for corporate citizenship and philanthropy, partnerships
toward sustainable health care, codes of conduct and compliance, and
operational eco-efficiency. Jeannine M. Rivet, Executive Vice President,
UnitedHealth, said, "The people of this enterprise are dedicated to a culture
of integrity, compassion, relationships, innovation and performance. Our focus
on achieving these defining traits informs the decisions we make and guides
our businesses in serving the health benefits and services needs of millions
of consumers, physicians and other care providers, employers, government and
other benefit sponsors. We are honored to be recognized for the work we do
every day to make high-quality health care more accessible and affordable for
more people." The Full Research Report on UnitedHealth Group Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:


Bristol-Myers Squibb Co. Research Report

On September 12, 2013, Bristol-Myers Squibb Co. (Bristol-Myers) reported
results from the Phase 3, randomized, double-blind clinical trial (Study 043)
comparing Yervoy 10 mg/kg (ipilimumab) (n=399) to placebo (n=400) following
radiation in patients with advanced metastatic castration-resistant prostate
cancer (mCRPC) who have received prior treatment with docetaxel. The Company
revealed that the study's primary endpoint of overall survival (OS) did not
reach statistical significance (HR = 0.85; 95% CI = 0.72-1.00; p = 0.053).
Nevertheless, the Company stated that anti-tumor activity was observed across
some efficacy endpoints, including progression free-survival. W. R. Gerritsen,
M.D., Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, said,
"Although the study did not meet its primary endpoint, clinical activity was
observed in this Phase 3 trial with a suggestion of greater activity in those
with less advanced castration-resistant prostate cancer. These results offer
important insights for ongoing and future studies of Yervoy in prostate
cancer, including a second large trial of Yervoy in patients with less
advanced disease." The Full Research Report on Bristol-Myers Squibb Co. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:



1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
5.For any urgent concerns or inquiries, please contact us at
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.


Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.


Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.


Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA


SOURCE Investors' Reports

Contact: Kristi Saunders, CONTACT PHONE: +1-315-982-6420 (North America)
Press spacebar to pause and continue. Press esc to stop.